Lv1
10 积分 2023-02-28 加入
T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603 Study
3个月前
已完结
Radiotheranostic landscape: A review of clinical and preclinical development
4个月前
已完结
An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity
6个月前
已完结
Covalent targeted radioligands potentiate radionuclide therapy
6个月前
已完结
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
9个月前
已完结
Insights into recent findings and clinical application of YAP and TAZ in cancer
1年前
已完结
Abstract 1656: ISM6331, a novel and potent pan-TEAD inhibitor, exhibits strong anti-tumor activity in preclinical models of Hippo pathway-dysregulated cancers
1年前
已关闭
A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
1年前
已完结
Preventive effects of Ramelteon on bleomycin-induced pulmonary fibrosis in mice
1年前
已完结
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers
1年前
已完结
皖公网安备34019202002308
